eligibility_summary
Incl: adults 18–75, ECOG 0–1, ≥3 mo survival, adequate organs and LVEF ≥50%, prior tox ≤G1, advanced/metastatic urothelial or other solid tumors post‑standard failure, provide tumor tissue, ≥1 measurable non‑prostate lesion, prostate ca: castrate T <1.73 nmol/L with progression. Excl: recent therapy, major CV/QT disease, autoimmune, other active cancers, uncontrolled DM/HTN, ILD/severe lung, immunosuppression, thrombosis, CNS mets, effusions/major‑vessel invasion, serious infection, transplant, active HIV/TB/HBV/HCV, bleeding/wounds, live vaccines.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Single-arm Phase IIa/IIb of BL-B01D1 in adults with advanced solid tumors, including urothelial cancers, after standard therapy failure. Drug/intervention: BL-B01D1 (iza-bren, izalontamab brengitecan, BMS-986507) given IV. Type/mechanism: Antibody–drug conjugate (ADC). The mAb binds a tumor-associated surface antigen (target antigen not specified in the record), is internalized, and releases a camptothecin-class topoisomerase I inhibitor payload (“-tecan”), causing DNA damage and tumor cell death. Cells/pathways targeted: Antigen-positive epithelial tumor cells, intracellular topoisomerase I and DNA replication/repair pathways (replication fork stress and double-strand breaks). Objectives: safety, tolerability, PK, immunogenicity, and antitumor activity at RP2D.